<DOC>
	<DOC>NCT00187252</DOC>
	<brief_summary>The purpose of this study is to evaluate whether adding AF Suppression™ to cardiac resynchronization therapy (CRT) improves the prognosis of heart failure patients benefiting from cardiac resynchronization therapy.</brief_summary>
	<brief_title>Mascot Study: Management of Atrial Fibrillation (AF) Suppression in AF-Heart Failure (HF) COmorbidity Therapy</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<criteria>HF patients New York Heart Association (NYHA) III IV Spontaneous QRS ≥130 ms and/or mechanical interventricular delay &gt; 50 ms Left ventricular ejection fraction (LVEF) ≤ 35% Left ventricular end diastolic diameter (LVEDD) ≥ 55 mm Optimized medical regimen Age &gt; 18 years Unstable angina or acute myocardial infarction (MI) (&lt; 3 months) Coronary artery bypass grafting (CABG) or percutaneous transluminal coronary angioplasty (PTCA) &lt; 3 months Life expectancy &lt; 6 months Permanent AF Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Ventricular Dyssynchrony</keyword>
</DOC>